<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521297</url>
  </required_header>
  <id_info>
    <org_study_id>PBC-UDCA</org_study_id>
    <nct_id>NCT03521297</nct_id>
  </id_info>
  <brief_title>Probiotics in PBC Patients of Poor Response to UDCA</brief_title>
  <official_title>Safety and Efficacy of Probiotics in Primary Biliary Cholangitis (PBC) Patients With Poor Ursodeoxycholic Acid (UDCA) Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of probiotics in primary biliary cholangitis (PBC) patients with poor
      ursodeoxycholic acid (UDCA) response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PBC patients with poor ursodeoxycholic acid (UDCA) response are selected and randomly
      assigned into probiotic group and control group. Patients in probiotic group receive
      probiotic(Micro V Probiotics) combined UDCA for 6 months and then continue to take UDCA
      alone. Patients in control group continue to take UDCA alone. Biochemical indicators,
      immunological indicators, liver stiffness, and ultrasound of the two groups of patients were
      collected. GLOBE and UK-PBC scoring system are used to assesse prognosis.The feces and serum
      of all patients are collected to observe the differences in fecal microbial polymorphisms in
      the two groups of patients. Metabolomics are used to study the differences in the bile acids
      and short chain fatty acid metabolites of the serum and feces of the two groups of PBC
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>single(Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical response</measure>
    <time_frame>6 month</time_frame>
    <description>Percentage of patients with biochemical response (serum ALP(U/L) or GGT(U/L) decreased by 20% from baseline)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Biliary Cholangitis (PBC)</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>UDCA combined probiotic</description>
    <arm_group_label>Probiotics group</arm_group_label>
    <other_name>Probiotic group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>UDCA combined placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. PBC patients (diagnosed with PBC according to 2009 AASLD PBC PRACTICE GUIDANCE), take
             UDCA more than 12 months and have poor response;

          2. Age 18-70 years.

        Exclusion Criteria:

          1. Any other liver disesases (viral hepatitis, HIV positive, alcohol abuse,
             hemochromatosis, hepatolenticular degeneration, Î±1-antitrypsin deficiency and so on);

          2. Important organ dysfunction such as heart, lung and kidney which affect the life
             expectancy;

          3. Have congenital galactosemia, glucose malabsorption syndrome or lactase deficiency.

          4. Patients allergic to research drugs or excipients;

          5. Pregnant or lactating women;

          6. Not signed informed consent;

          7. Have antibiotics one month before enrollment;

          8. Microecological preparations (probiotics, prebiotics, synbiotics, etc.) were used
             before the enrollment;

          9. Malignant tumors, nerves and mental disorders;

         10. Those who participated in other drug clinical trials in the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bingliang Lin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Third Affliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bingliang Lin, MD</last_name>
    <phone>13924129928</phone>
    <email>lamikin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin B Liang, MD</last_name>
      <phone>86-20-85253165</phone>
      <email>lamikin@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>ursodeoxycholic acid (UDCA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

